Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation
Open Access
- 8 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (12) , 966-988
Abstract
BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH. METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH. RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling. CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.Keywords
This publication has 100 references indexed in Scilit:
- Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertensionNature Medicine, 2012
- Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activityNature Chemical Biology, 2011
- Redox compartmentalization and cellular stressDiabetes, Obesity and Metabolism, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial HypertensionCirculation, 2010
- Redox Control of the Cell Cycle in Health and DiseaseAntioxidants & Redox Signaling, 2009
- Resveratrol Prevents Monocrotaline-Induced Pulmonary Hypertension in RatsHypertension, 2009
- The structure of CDK4/cyclin D3 has implications for models of CDK activationProceedings of the National Academy of Sciences, 2009
- Crystal structure of human CDK4 in complex with a D-type cyclinProceedings of the National Academy of Sciences, 2009
- An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseJournal of the American Society for Mass Spectrometry, 1994